Literature DB >> 26517559

Activation and Allosteric Modulation of Human μ Opioid Receptor in Molecular Dynamics.

Damian Bartuzi1, Agnieszka A Kaczor1,2, Dariusz Matosiuk1.   

Abstract

Allosteric protein modulation has gained increasing attention in drug design. Its application as a mechanism of action could bring forth safer and more effective medicines. Targeting opioid receptors with allosteric modulators can result in better treatment of pain, depression, and respiratory and immune disorders. In this work we use recent reports on negative modulators of μ opioid receptor as a starting point for identification of allosteric sites and mechanisms of opioid receptor modulation using homology modeling and docking and molecular dynamics studies. An allosteric binding site description is presented. Results suggest a shared binding region for lipophilic allosteric ligands, reveal possible differences in the modulation mechanism between cannabinoids and salvinorin A, and show ambiguous properties of the latter. Also, they emphasize the importance of native-like environment in molecular dynamics simulations and uncover relationships between modulator and orthosteric ligand binding and receptor behavior. Relationships between ligands, transmission switch, and hydrophobic lock are analyzed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26517559     DOI: 10.1021/acs.jcim.5b00280

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  16 in total

Review 1.  Allostery at opioid receptors: modulation with small molecule ligands.

Authors:  Kathryn E Livingston; John R Traynor
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

Review 2.  An overview of recent molecular dynamics applications as medicinal chemistry tools for the undruggable site challenge.

Authors:  Ugo Perricone; Maria Rita Gulotta; Jessica Lombino; Barbara Parrino; Stella Cascioferro; Patrizia Diana; Girolamo Cirrincione; Alessandro Padova
Journal:  Medchemcomm       Date:  2018-04-19       Impact factor: 3.597

3.  Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.

Authors:  A F Marmolejo-Valencia; K Martínez-Mayorga
Journal:  J Comput Aided Mol Des       Date:  2017-03-31       Impact factor: 3.686

4.  Biased agonism and allosteric modulation of G protein-coupled receptor 183 - a 7TM receptor also known as Epstein-Barr virus-induced gene 2.

Authors:  Viktorija Daugvilaite; Christian Medom Madsen; Michael Lückmann; Clara Castello Echeverria; Andreas Walter Sailer; Thomas Michael Frimurer; Mette Marie Rosenkilde; Tau Benned-Jensen
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

5.  Synthetic and Natural Derivatives of Cannabidiol.

Authors:  Paula Morales; Nadine Jagerovic
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.

Authors:  David R Janero; Ganesh A Thakur
Journal:  Expert Opin Drug Discov       Date:  2016-10-21       Impact factor: 6.098

7.  Encoding mu-opioid receptor biased agonism with interaction fingerprints.

Authors:  R Bruno Hernández-Alvarado; Abraham Madariaga-Mazón; Fernando Cosme-Vela; Andrés F Marmolejo-Valencia; Adel Nefzi; Karina Martinez-Mayorga
Journal:  J Comput Aided Mol Des       Date:  2021-10-29       Impact factor: 3.686

8.  Understanding the molecular basis of agonist/antagonist mechanism of human mu opioid receptor through gaussian accelerated molecular dynamics method.

Authors:  Yeng-Tseng Wang; Yang-Hsiang Chan
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

9.  Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt1]DALDA, and KGOP01, Binding to the mu Opioid Receptor.

Authors:  Maria Dumitrascuta; Marcel Bermudez; Steven Ballet; Gerhard Wolber; Mariana Spetea
Journal:  Molecules       Date:  2020-04-29       Impact factor: 4.411

10.  Novel variants of engineered water soluble mu opioid receptors with extensive mutations and removal of cysteines.

Authors:  Jin Xi; Nanmu Yang; Jose Manuel Perez-Aguilar; Bernard Selling; John R Grothusen; Rajan Lamichhane; Jeffery G Saven; Renyu Liu
Journal:  Proteins       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.